共 50 条
- [31] A Phase 1 First-in-Human Study of Abbv-383, a BCMA x CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple MyelomaBLOOD, 2022, 140 : 4401 - 4404Voorhees, Peter M.D'Souza, AnitaWeisel, KatjaHurd, David DuaneTeipel, RaphaelChung, AlfredRodriguez, CesarTuchman, Sascha A.Korde, NehaSafah, HanaBueno, Orlando F.Pumford, NeilRosenberg, Tanya S.Pothacamury, Rajvineeth KumarRoss, Jeremy A.Polepally, Akshanth R.Lee, ShaneJin, ZiyiTalati, ChetasiVij, RaviKumar, Shaji K.
- [32] Predictive Biomarkers of Response to Venetoclax in Combination with Cobimetinib in Relapsed/Refractory Multiple Myeloma (RRMM)BLOOD, 2020, 136Raval, AparnaHamidi, HabibHwang, OliviaGreen, CherieMaia, CatarinaLasa, MartaOnishi, MaikaRodriguez-Otero, PaulaSan-Miguel, Jesus F.Gallo, Jorge D.Paiva, BrunoSchjesvold, Fredrik
- [33] Exposure-Response of Quizartinib Efficacy in Patients with Relapsed/Refractory AMLBLOOD, 2019, 134Kang, DongwooPassarell, JulieAbutarif, Malaz A.Mendell, JeanneYin, Ophelia
- [34] Updated results of a phase 1, first-in-human study of ABBV-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S34 - S34Voorhees, PeterShah, NinaD'Souza, AnitaRodriguez, CesarWeisel, KatjaTeipel, RaphaelHurd, DavidBueno, OrlandoPumford, NeilRosenberg, TanyaPothacamury, Rajvineeth KumarRoss, JeremyPolepally, AkshanthLee, ShaneJin, ZiyiTalati, ChetasiKumar, ShajiVij, Ravi
- [35] EXPOSURE-SAFETY-EFFICACY ANALYSIS OF IXAZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DOSE SELECTION FOR PHASE III TRIAL OF IXAZOMIB MAINTENANCE THERAPYCLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S13 - S14Gupta, N.Labotka, R.Liu, G.Venkatakrishnan, K.
- [36] Exposure-response analysis of venetoclax in combination with carfilzomib and dexamethasone in t(11;14)-positive relapsed/refractory multiple myeloma patientsCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S161 - S162Badawi, MohamedEngelhardt, BenjaminDobkowska, EdytaDeng, RongKaufman, JonathanMenon, RajeevSalem, Ahmed Hamed
- [37] Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment ExposureBLOOD, 2012, 120 (21)Vij, RaviHofmeister, Craig C.Richardson, Paul G.Jagannath, SundarSiegel, David S.Baz, RachidChen, MinZaki, MohamedLarkins, GailAnderson, Kenneth C.
- [38] Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and DexamethasoneBLOOD, 2022, 140 : 10122 - 10123Badawi, Mohamed A.Engelhardt, BenjaminBadillo, JesusSuleiman, Ahmed AbbasFleming, Leanne LashLuo, YanKaufman, Jonathan L.Bahlis, Nizar JacquesMenon, RajeevSalem, Ahmed Hamed
- [39] Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple MyelomaADVANCES IN THERAPY, 2018, 35 (11) : 1859 - 1872Xu, Xu StevenDimopoulos, Meletios A.Sonneveld, PieterHo, P. JoyBelch, AndrewLeiba, MeravCapra, MarceloGomez, DavidMedvedova, EvaIida, ShinsukeMin, Chang-KiSchecter, JordanJansson, RichardZhang, LipingSun, Yu-NienClemens, Pamela L.